Christina Sewell

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai, Anjali Owens, Jeffrey B. Geske et al. · Journal of the American College of Cardiology · 2022 · 353 citations · Full text

Medicine, Cardiology, Pharmacotherapy +12

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

Milind Y. Desai, Anjali Owens, Kathy Wolski et al. · JAMA Cardiology · 2023 · 156 citations · Full text

Medicine, Cardiology, Pharmacotherapy +11

Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks

Milind Y. Desai, Anjali Owens, Jeffrey B. Geske et al. · Circulation · 2022 · 89 citations

Medicine, Cardiology, Pharmacology +13

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Paul Cremer, Antonio Abbate, Kristin Hudock et al. · The Lancet Rheumatology · 2021 · 69 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy

Milind Y. Desai, Kathy Wolski, Anjali Owens et al. · American Heart Journal · 2021 · 62 citations

Medicine, Cardiology, Internal Medicine +5